摘要
目的探讨肿瘤坏死因子受体6（TR-6）蛋白在原发性肝细胞癌（HCC）组织芯片及肝癌细胞系中的表达及临床意义。方法利用125例HCC、48例癌旁、89例非癌肝组织构建组织微阵列。应用免疫组织化学法检测组织芯片和5种肝癌细胞系中TR-6蛋白的表达水平，并分析其与HCC临床病理特征的关系。结果（1）组织微阵列利用率为96．56％（253／262）；（2）HCC组织中的TR-6蛋白的阳性率为73．33％（88／120），明显高于癌旁的54．17％（26／48，x^2=5．755，P=0．016）及非癌组织的29．41％（25／85，x^2=38．801，P=0．000）。癌旁组织中的TR-6蛋白阳性率明显高于非癌组织（x^2=7．952，P=0．005）。5种肝癌细胞系均有TR-6蛋白的表达，而癌旁肝细胞系QSG-7701及正常肝细胞系HL-7702均无表达；（3）HCC中临床TNM分期Ⅰ、Ⅱ期TR-6阳性率61．76％（42／68）明显低于Ⅲ、Ⅳ期88．46％（46／52，x^2=10．739，P=0．001）；（4）HCC中无转移组TR-6阳性率58．82％（20／34）明显低于转移组96．67％（29／30，x^2=19．858，P=0．000）；（5）TR-6表达率在AFP≥400μg／L组为80．82％（59／73）、有门静脉癌栓组91．30％（42／46）、包膜浸润组84．34％（70／83）和多个肿瘤结节组89．13％（41／46）分别高于AFP〈400μg／L组的61．70％（29／47，x^2=5．345，P=0．021）、无门静脉癌栓组的62．16％（46／74，x^2=12．319，P=0．000）、无包膜浸润组的48．65％（18／37，x^2=16．668，P=0．000）及单个肿瘤结节组的63．51％（47／74，x^2=9．519，P=0．002）。（6）TR-6表达与年龄、性别、肿瘤分化程度、有无肝硬化及肿瘤直径无关。结论检测TR-6蛋白指标有助于HCC的诊断和判断患者预后。
Objective To investigate the expression of TR-6 protein in hepatic tissue microarrays and hepatocellular carcinoma （HCC） cell lines and its clinical significance. Methods Hepatic tissue microarrays of 125 cases of HCC tissues, 48 adjacent liver tissues and 89 non-cancerous liver tissues were made. Immunochemistry was employed to detect the expression of TR-6 proteins in the tissue microarrays and 5 HCC cell lines and 2 non-cancerous hepatic cell lines. Results （ 1 ） There were 253 cases that could be used in the tissue microarrays （ utilization rate was 96.56% , 253/262） ; （2） The positive rate of TR-6 in HCC tissues was 73.33% （88/120）, significantly higher than that in the adjacent-tumor liver tissues 54. 17 % （ 26/48, x^2 = 5. 755, P = 0.016） and non-cancerous liver tissues 29. 41% （25/85, x^2 = 38. 801, P = 0. 000）. The positive rate of TR-6 in adjacent-tumor tissues was significantly higher that that in the non-cancerous group（ x^2 = 7.952, P = 0. 005 ）. TR-6 protein was positive in all the 5 HCC cell lines while negative in noncancer cell lines QSG-7701 and HL-7702; （3）The positive rate of TR-6 in HCC tissues in the clinical TNM stage Ⅰ , Ⅱ was 61.76% （42/68）, obviously lower than 88.46% in stage Ⅲ, Ⅳ （46/52 ,x^2 = 10. 739,P =0. 001 ） ;（4）The positive rate of TR-6 in the cases without metastasis within 20 months follow-up was 58.82% （ 20/34）, significantly lower than 96. 67% in the group with metastasis （ 29/30, x^2 = 19. 858 ,P =0. 000）; （5）TR-6 expression rate in cases with AFP ≥400 μg/L （80. 82% ,59/73 ）, portal vein tumor embolus（ 91.30%, 42/46 ）, capsular infiltration （ 84. 34% , 70/83 ） and multiple tumor nodes （ 89.13 % ,41/46）were significantly higher than that in cases with AFP 〈 400 μg/L （61.70%, 29/47, x^2 =5. 345 ,P = 0. 021 ） ,without tumor embolus （62. 16% ,46/74, x^2 = 12. 319, P = 0. 000） ,with no capsular infiltration （48.65%, 18/37, x^2 = 16. 668, P = 0. 000） and single tumor node （ 63.51% , 47/74, x^2 = 9. 519,P = 0. 002）. Conclusions TR-6 gene may serve as an important molecular biological indicator in diagnosing and predicating the biological behavior of HCC.
出处
《中华普通外科杂志》
CSCD
北大核心
2008年第1期44-47,共4页
Chinese Journal of General Surgery
基金
中国高等学校博士学科点专项科研基金资助项目（20050598005）
广西科学研究与技术开发计划应用基础研究项目基金资助项目（桂科基0639040）.志谢 感谢吕自力博士提供组织芯片的技术支持.
关键词
癌
肝细胞
受体
肿瘤坏死因子
免疫化学
组织芯片
细胞系
Carcinoma, hepatocellular
Receptors, tumor necrosis factor
Immunochemistry
Tissue array
Cell lines
